Alumis (NASDAQ:ALMS) Director Purchases $540,100.86 in Stock

Alumis Inc. (NASDAQ:ALMS) Director Srinivas Akkaraju bought 66,027 shares of Alumis stock in a transaction dated Thursday, December 4th. The stock was acquired at an average cost of $8.18 per share, for a total transaction of $540,100.86. Following the completion of the acquisition, the director directly owned 1,078,876 shares in the company, valued at $8,825,205.68. This represents a 6.52% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Srinivas Akkaraju also recently made the following trade(s):

• On Wednesday, December 3rd, Srinivas Akkaraju purchased 100,000 shares of Alumis stock. The shares were acquired at an average cost of $7.75 per share, with a total value of $775,000.00.
• On Tuesday, December 2nd, Srinivas Akkaraju acquired 96,000 shares of Alumis stock. The stock was acquired at an average cost of $7.55 per share, for a total transaction of $724,800.00.
• On Monday, December 1st, Srinivas Akkaraju bought 86,350 shares of Alumis stock. The stock was acquired at an average price of $7.46 per share, with a total value of $644,171.00.
• On Friday, November 28th, Srinivas Akkaraju acquired 38,702 shares of Alumis stock. The stock was bought at an average price of $7.64 per share, with a total value of $295,683.28.
• On Wednesday, November 26th, Srinivas Akkaraju acquired 48,537 shares of Alumis stock. The stock was bought at an average price of $7.64 per share, with a total value of $370,822.68.
• On Thursday, November 20th, Srinivas Akkaraju acquired 125,743 shares of Alumis stock. The shares were purchased at an average cost of $7.20 per share, for a total transaction of $905,349.60.
• On Wednesday, November 19th, Srinivas Akkaraju bought 137,772 shares of Alumis stock. The shares were purchased at an average price of $6.56 per share, with a total value of $903,784.32.
• On Tuesday, November 18th, Srinivas Akkaraju purchased 102,652 shares of Alumis stock. The shares were purchased at an average cost of $6.05 per share, for a total transaction of $621,044.60.
• On Monday, November 17th, Srinivas Akkaraju purchased 914 shares of Alumis stock. The stock was purchased at an average price of $5.51 per share, for a total transaction of $5,036.14.
• On Thursday, November 13th, Srinivas Akkaraju acquired 276,179 shares of Alumis stock. The shares were purchased at an average cost of $5.25 per share, with a total value of $1,449,939.75.

Alumis Stock Performance

Alumis stock traded up $0.46 during trading hours on Thursday, reaching $8.30. 1,265,947 shares of the company’s stock traded hands, compared to its average volume of 1,217,871. Alumis Inc. has a fifty-two week low of $2.76 and a fifty-two week high of $10.49. The firm’s 50 day moving average is $5.33 and its 200-day moving average is $4.44.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.14). The company had revenue of $2.07 million for the quarter, compared to analyst estimates of $3.14 million. Equities analysts anticipate that Alumis Inc. will post -8.51 earnings per share for the current year.

Hedge Funds Weigh In On Alumis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Samsara Biocapital LLC raised its position in Alumis by 47.0% in the 2nd quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock valued at $14,404,000 after buying an additional 1,534,872 shares during the last quarter. Foresite Capital Management VI LLC grew its stake in shares of Alumis by 1.1% during the 2nd quarter. Foresite Capital Management VI LLC now owns 4,247,670 shares of the company’s stock worth $12,743,000 after acquiring an additional 45,000 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Alumis by 18.4% in the third quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company’s stock valued at $16,078,000 after purchasing an additional 625,404 shares during the last quarter. Trium Capital LLP lifted its position in shares of Alumis by 17.9% in the third quarter. Trium Capital LLP now owns 3,122,111 shares of the company’s stock worth $12,457,000 after purchasing an additional 474,072 shares in the last quarter. Finally, Orbimed Advisors LLC acquired a new position in Alumis during the second quarter worth $5,779,000.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Alumis in a research note on Tuesday, November 25th. HC Wainwright reiterated a “buy” rating and issued a $14.00 price target on shares of Alumis in a research report on Thursday, August 14th. Morgan Stanley reduced their price objective on shares of Alumis from $23.00 to $22.00 and set an “overweight” rating on the stock in a research note on Friday, August 15th. Finally, Wall Street Zen downgraded shares of Alumis from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Alumis has an average rating of “Moderate Buy” and an average price target of $19.20.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.